Testoderm is a drug owned by Alza Corp. It is protected by 1 US drug patent filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Aug 15, 2016. Details of Testoderm's patents and their expiration are given in the table below.
Filter patents by
Country
: United States (US)
Argentina (AR)
Australia (AU)
Brazil (BR)
Canada (CA)
Chile (CL)
China (CN)
India (IN)
Japan (JP)
Mexico (MX)
Paraguay (PY)
Philippines (PH)
Russia (RU)
Singapore (SG)
South Africa (ZA)
Thailand (TH)
United States (US)
Uruguay (UY)
Eurasian Patent Organization (EA)
World Intellectual Property Organization (WO)
Taiwan (TW)
European Patent Office (EP)
Patent Category
: All
All
Combination
Compound
Device
Dosage Regimen
Formulation
Other Forms
Polymorph
Process
Use Method
Dosage Form Category
: Others
Implantable
Inhalation
Injectable
OPHTHALMIC
Oral Liquid
Oral Solid
Rectal/Vaginal
Topical
Transdermal
Others
NEW
Get the complete list right in your inbox!
Contact Us
Drug Patent Number
Drug Patent Title
Drug Patent Expiry
Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration
(oral, tablet,
capsules, liquids etc).
Transdermal drug delivery device having enhanced adhesion
Aug, 2016
(10 years ago)
Expired
Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.
Get the exclusive patent insights now. Don't be the last to know.
US patents provide insights into the exclusivity only within the United States, but
Testoderm is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Testoderm's family patents as well as insights into
ongoing legal events
on those patents.
Testoderm's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List
Clinical Trials
Recent Clinical Trials on Testoderm:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
Testoderm's
generic launch date based on the expiry of its last outstanding patent is estimated to be Aug 15, 2016 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Testoderm Generic
API
suppliers:
Testosterone is the generic name
for
the brand Testoderm.
14 different companies have already filed for the generic of Testoderm, with Actavis Labs Ut Inc having the maximum number of approved applications.
Check out the entire list of companies
who have already received approval for Testoderm's
generic
Alternative Brands for
Testoderm
There are several other brand drugs using the same active ingredient (Testosterone) as Testoderm.
Given below is the list of those companies and their brand drugs, to help you identify new
opportunities, assess
competitors, and plan your market strategies more effectively.
